

## THC BioMed Form 7

### MONTHLY PROGRESS REPORT

August 2020

Name of CSE Issuer **THC BioMed Intl Ltd. ("THC BioMed")**  
Trading Symbol: **THC**  
Number of Outstanding Listed Securities **158,426,056 common shares and 52,036,951 reserved for Issuance**  
Date: **September 2, 2020**

#### Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

During the period, THC BioMed received notice from the U.S. Patent and Trademark Office ("USPTO") that it had allowed the patent application for THC BioMed's Clone Shipper Constant Illuminated, Tamper Resistant Plant Container. THC BioMed expects to receive an Issue Notification Letter from the USPTO approximately 3 weeks prior to the official issuance date of the patent.

As noted in the title, the container provides the plant inside it with a constant source of light and helps plants do very well during shipping. The container is also tamper-resistant, which is important for shipping plants such as cannabis clones.

Also during the period, THC BioMed has been focused on product development and sales for "Cannabis 2.0," with edibles and beverages. They have submitted three new products to Health Canada for the 60-day notice period. Please see Item #3 below for more details.

On August 25, the Issuer announced that it had received a purchase order from the Ontario Cannabis Store ("OCS") for the THC Kiss Beverage Shot. The Issuer immediately started preparing the order for shipment.

"We are extremely proud of our team in achieving this milestone. We believe that the THC Kiss Beverage Shot offers a true alternative to smoking cannabis," commented John Miller, THC BioMed's CEO.

THC BioMed began selling THC Pure Cannabis Sticks @\$4.20 per Stick through THC BioMed's online store for medical patients.

Penelope Laine has temporarily resigned from the Issuer's board of directors until Health Canada completes its standard security clearance for directors. Ms. Laine will continue to work with the Issuer as an advisor until the security clearance procedure has been completed.

2. Provide a general overview and discussion of the activities of management.

**Management continues to work on the conduct of the company's business plan, growth and harvest of product, new product testing and expansion plans.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**THC BioMed has been focused on product development and sales for "Cannabis 2.0," with edibles and beverages. It has submitted the following new products to Health Canada for the 60-day notice period for new products:**

**THC Kiss Gummies**

**THC BioMed's latest product, THC Kiss Gummies, are tasty gummy candies containing 2.5 mg of THC each. They will come with 4 in a package (10 mg.) The cannabis extract used is from the same proprietary extraction system as that used in THC Kiss beverage shot.**

**THC Kiss Water**

**THC BioMed also announced that a new product, Kiss Water, has been submitted to Health Canada. THC Kiss Water is a refreshing beverage with a slight herbal taste. Each 220 ml beverage contains 3 mg of THC.**

**THC Kiss Chocolate**

**THC Kiss Chocolate has been formulated with the same cannabis extract used is from the same proprietary extraction system as that used in THC Kiss beverage shot and THC Kiss Gummies. The extract is designed to be fast acting and uplifting and to provide a realistic and great-tasting alternative to smoking cannabis.**

**THC Pure Cannabis Sticks**

**THC Pure Cannabis Sticks are now available on THC BioMed's online store for medical patients @\$4.20 per Stick.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**On August 25, the Issuer announced that it had received a purchase order from the Ontario Cannabis Store (“OCS”) for the THC Kiss Beverage Shot.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None.**

8. Describe the acquisition of new customers or loss of customers.

**The Issuer has continued to register new patients.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

**On August 24, THC BioMed received notice from the U.S. Patent and Trademark Office (“USPTO”) that it had allowed the patent application for THC BioMed’s Clone Shipper Constant Illuminated, Tamper Resistant Plant Container. THC BioMed expects to receive an Issue Notification Letter from the USPTO approximately 3 weeks prior to the official issuance date of the patent.**

**As noted in the title, the container provides the plant inside it with a constant source of light and helps plants do very well during shipping. The container is also tamper-resistant, which is important for shipping plants such as cannabis clones.**

10. Report on any employee hiring’s, terminations or lay-offs with details of anticipated length of lay-offs.

**None, except in the ordinary course of business.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**None.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None.**

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
<b>None</b>	<b>None</b>	<b>None</b>	<b>None</b>

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

**None.**

16. Provide details of any changes in directors, officers or committee members.

**On August 25, THC BioMed announced that Penelope Laine has temporarily resigned from the Issuer’s board of directors until Health Canada completes its standard security clearance for directors. Ms. Laine will continue to work with the Issuer as an advisor until the security clearance procedure has been completed.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**The Issuer’s business involves certain risks and uncertainties that are inherent to the Issuer’s industry. For disclosure on risks related to an investment in the Issuer, please refer to the Issuer’s most recent Management’s Discussion and Analysis under the titles “Financial Instruments and Risk Management” and “Other Risks and Uncertainties”, which is available on SEDAR at [www.sedar.com](http://www.sedar.com).**

**The outbreak of COVID-19 has significantly increased economic uncertainty. In addition, public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions and the adoption of remote working, have impacted our business and operations. COVID-19 is impacting our contractors’ ability to provide services to us, including professional services such as accounting and auditing due to social distancing measures.**

**Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **September 2, 2020.**

**John Miller**  
 \_\_\_\_\_  
 Name of Director or Senior Officer

***“John Miller”***  
 \_\_\_\_\_  
 Signature

**President and CEO**  
 \_\_\_\_\_  
 Official Capacity

<b><i>Issuer Details</i></b>		
Name of Issuer: <b>THC BioMed Intl Ltd.</b>	For Month End <b>August</b>	Date of Report: YYYYMMDD <b>2020/09/</b>
Issuer Address: <b>P.O. Box 20033 Towne Centre</b>		
City/Province/Postal Code: <b>Kelowna, BC V1Y 9H2</b>	Issuer Fax No.: <b>N/A</b>	Issuer Telephone No. <b>(250) 870-2512</b>
Contact Name: <b>John Miller</b>	Contact Position: <b>President &amp; CEO</b>	Contact Telephone No. <b>(250) 870-2512</b>
Contact Email Address: <b>info@thcbiomed.com</b>	Web Site Address: <b>www.thcbiomed.com</b>	